Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY |
NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated
financial results for the quarter and the nine months ended
December 31, 2020. The information mentioned in this release is on
the basis of consolidated financial statements under International
Financial Reporting Standards (IFRS).
Q3 Performance
Summary
9M Performance
Summary
Rs. 4,930 Cr
Rs. 14,244 Cr
Revenue
Revenue
[Up: 12% YoY; 1% QoQ]
[Up: 9% YoY]
53.8%
54.6%
Gross Margin
Gross Margin
[Q3 FY20: 54.1%; Q2 FY21: 53.9%]
[9M FY20: 54.7%]
Rs.1,439 Cr
Rs. 4,028 Cr
SGNA expenses
SGNA expenses
[Up: 14% YoY; 10% QoQ]
[Up: 6% YoY]
Rs. 411 Cr
Rs. 1,245 Cr
R&D expenses
R&D expenses
[8.3% of Revenues]
[8.7% of Revenues]
Rs. 1,185 Cr
Rs. 3,615 Cr
EBITDA
EBITDA
[24.0% of Revenues]
[25.4% of Revenues]
Rs. 284 Cr*
Rs. 2,025 Cr
Profit before Tax
Profit before Tax
[5.8% of Revenues]
[14.2% of Revenues]
Rs. 20 Cr**
Rs. 1,361 Cr
Profit after Tax
Profit after Tax
[0.4% of Revenues]
[9.6% of Revenues]
*Excluding the impairment charge in Q3 FY21, the Profit before
Tax is Rs. 882 cr **Q3 FY21 Profit after Tax was impacted primarily
due to non-recognition of deferred tax asset on impairment
Commenting on the results, Co-chairman & MD, G V Prasad
said, “We continued with our growth momentum while maintaining
EBITDA margins. The profits were impacted due to trigger based
impairment charge taken on a few acquired products including
Nuvaring. We are progressing well on the phase 3 clinical trials
for Sputnik V vaccine in India. We continue to focus on enhancing
our product offerings to our patients to serve them better.”
All amounts in millions, except EPS. All US dollar amounts based
on convenience translation rate of I USD = Rs. 73.01
Dr.
Reddy’s Laboratories Limited and Subsidiaries
Consolidated Income
Statement
Particulars
Q3 FY21
Q3 FY20
YoY Gr %
Q2 FY21
QoQ Gr %
($)
(Rs.)
($)
(Rs.)
($)
(Rs.)
Revenues
675
49,296
600
43,838
12
671
48,967
1
Cost of Revenues
312
22,758
276
20,116
13
309
22,558
1
Gross Profit
363
26,538
325
23,722
12
362
26,409
0
Operating Expenses
Selling, General & Administrative
expenses
197
14,387
174
12,670
14
180
13,107
10
Research and Development expenses
56
4,108
54
3,949
4
60
4,359
(6
)
Impairment of non-current assets
82
5,972
181
13,200
(55
)
11
781
665
Other operating income
(2
)
(128
)
(3
)
(228
)
(44
)
(2
)
(149
)
(14
)
Results from operating
activities
30
2,199
(80
)
(5,869
)
-
114
8,311
(74
)
Net finance income
(7
)
(493
)
(6
)
(419
)
18
(3
)
(237
)
108
Share of profit of equity accounted
investees
(2
)
(151
)
(2
)
(176
)
(14
)
(1
)
(73
)
107
Profit / (loss) before Income
Tax
39
2,843
(72
)
(5,274
)
-
118
8,621
(67
)
Income Tax
36
2,645
6
423
525
14
998
165
Profit / (loss) for the period
3
198
(78
)
(5,697
)
-
104
7,623
(97
)
Diluted Earnings Per Share
(EPS)
0.02
1.19
(0.47
)
(34.37
)
-
0.63
45.83
(97
)
As % to revenues
Q3 FY21
Q3 FY20
Q2 FY21
Gross Profit
53.8
54.1
53.9
SG&A
29.2
28.9
26.8
R&D
8.3
9.0
8.9
EBITDA
24.0
24.5
25.9
PBT
5.8
(12.0
)
17.6
PAT
0.4
(13.0
)
15.6
EBITDA Computation
Particulars
Q3 FY21
Q3 FY20
Q2 FY21
($)
(Rs.)
($)
(Rs.)
($)
(Rs.)
Profit before Income Tax
39
2,843
(72
)
(5,274
)
118
8,621
Interest income (net)*
(2
)
(180
)
(4
)
(274
)
(0
)
(1
)
Depreciation
29
2,131
29
2,130
30
2,188
Amortization
15
1,086
13
955
15
1,084
Impairment
82
5,972
181
13,200
11
781
EBITDA
162
11,851
147
10,737
174
12,673
* Includes income from Investments
All amounts in millions, except EPS. All US dollar amounts based
on convenience translation rate of I USD = Rs. 73.01
Key Balance Sheet
Items
Particulars
As on 31st Dec 2020
As on 30th Sep 2020
As on 31st Dec 2019
($)
(Rs.)
($)
(Rs.)
($)
(Rs.)
Cash and cash equivalents and current
investments
291
21,282
357
26,074
280
20,457
Trade receivables (current &
non-current)
732
53,408
689
50,335
631
46,095
Inventories
607
44,309
563
41,134
517
37,746
Property, plant and equipment
771
56,263
754
55,026
722
52,709
Goodwill and Other Intangible assets
562
41,062
624
45,553
423
30,847
Loans and borrowings (current &
non-current)
280
20,443
376
27,429
224
16,320
Trade payables
316
23,072
313
22,833
244
17,810
Equity
2,320
1,69,395
2,265
1,65,337
2,036
1,48,672
Revenue Mix by Segment
Segment
Q3 FY21
Q3 FY20
YoY Gr %
Q2 FY21
QoQ Gr %
(Rs.)
(Rs.)
(Rs.)
Global Generics
40,751
35,927
13
39,841
2
North America
17,394
15,999
9
18,328
(5
)
Europe
4,143
3,093
34
3,754
10
India
9,591
7,636
26
9,123
5
Emerging Markets
9,623
9,199
5
8,636
11
Pharmaceutical Services and Active
Ingredients (PSAI)
7,009
6,906
1
8,505
(18
)
Proprietary Products &
Others
1,536
1,005
53
621
147
Total
49,296
43,838
12
48,967
1
Revenue Analysis
Global Generics (GG)
Revenues from GG segment at Rs. 40.8 billion:
- Year-on-year growth of 13% and sequential quarter growth of 2%,
primarily driven by new product launches and integration of the
acquired portfolio from Wockhardt in India. The volume growth in
the base business was largely offset by price erosion.
North America
Revenues from North America at Rs. 17.4 billion:
- Year-on-year growth of 9%, driven by new products launches,
increase in volumes of our base business and a favorable forex
rate, which was partially offset by price erosion.
- Sequential decline of 5%, primarily due to price erosion in
some of the key molecules.
- We launched four new products during the quarter. This included
Cinacalcet Tablets, Sapropterin Dihydrochloride Tablets and
Succinylcholine Chloride Injection in the US along with Daptomycin
Injection in Canada. We also re-launched one product in US - OTC
Famotidine.
- We filed two new ANDAs during the quarter. As of 31st December
2020, cumulatively 89 generic filings are pending for approval with
the USFDA (87 ANDAs and 2 NDAs under 505(b)(2) route). Of the 89
ANDAs, 48 are Para IVs and we believe 24 have ‘First to File’
status.
Europe
Revenues from Europe at Rs. 4.1 billion:
- Year-on-year growth of 34% and sequential growth of 10%, which
were driven by new product launches, favorable forex movement and
volume traction, offset partly by price erosion.
India
Revenues from India at Rs. 9.6 billion:
- Year-on-year growth of 26% and sequential growth of 5%. YoY
growth is on account of revenues from the acquired portfolio of
Wockhardt and contribution from new product launches. QoQ growth
was driven by volume traction.
Emerging Markets
Revenues from Emerging Markets at Rs. 9.6 billion.
Year-on-year growth of 5%. Sequential growth of 11%:
- Revenues from Russia at Rs. 4.5 billion. Year-on-year
decline of 8% is primarily due to weakening Ruble. Sequential
growth of 14% contributed by increased volumes
- Revenues from other CIS countries and Romania market at
Rs. 2.1 billion. Year-on-year growth of 18% and sequential growth
of 8% driven by both base business and new product launches.
- Revenues from Rest of World (RoW) territories at Rs. 3.0
billion. Year-on-year growth of 20% and sequential growth of 10% is
due to volume traction in the base business and new product
launches.
Pharmaceutical Services and Active Ingredients (PSAI)
Revenues from PSAI at Rs. 7.0 billion:
- Year-on-year growth of 1% driven by new products and favorable
forex rate, offset by lower volumes for some products.
- Sequential decline of 18% on account of lower volumes of
certain products.
- During the quarter we filed DMF for five products in the
US.
Proprietary Products (PP) & Others
Revenues from PP & Others at Rs. 1.5 billion:
- Year-on-year growth of 53% and sequential growth of 147%. The
growth was driven by milestone income received for the compound
AUR102.
Income Statement Highlights:
- Gross profit margin at 53.8%:
- Decline of 30 bps over previous year and 10 bps sequentially,
which was primarily impacted due to price erosion and lower export
benefits, partially offset by the milestone income received for the
compound AUR102.
- Gross profit margin for GG and PSAI business segments are at
57.6% and 25.3% respectively.
- SG&A expenses at Rs. 14.4 billion, increased by 14%
year-on-year primarily due to incremental costs post the
integration of the acquired portfolio from Wockhardt in this year
and increased freight expenses. Sequentially, it increased by 10%
primarily due to pickup in sales & marketing activities in
branded markets and increase in freight expenses.
- Impairment charge of Rs. 6.0 billion. In January, 2021
there has been an additional generic launch for the product
Nuvaring®, which has led to a considerable erosion in the value of
this product for us, and accordingly we have taken an impairment
charge of Rs. 3.2 billion. In addition to this, considering the
current market dynamics, we have taken an additional impairment
charge of Rs. 2.8 billion on the intangibles pertaining to other
products. We had an impairment charge of Rs. 13.2 billion in Q3 FY
20 and Rs. 781 million in Q2 FY21.
- R&D expenses at Rs. 4.1 billion. As % to revenues
these are: Q3 FY21: 8.3% | Q2 FY 21: 8.9% | Q3 FY20: 9.0%. Our
focus continues on building a healthy pipeline of new products
across our markets including development of products pertaining to
COVID-19 treatment.
- Other operating income at Rs. 128 million compared to
Rs. 228 million in Q3 FY20.
- Net Finance income at Rs. 493 million compared to Rs.
419 million in Q3 FY20.
- Profit before Tax at Rs. 2.8 billion, which is 5.8% of
revenues.
- Profit after Tax at Rs. 198 million. The effective tax
rate is ~93.0% for the quarter, impacted primarily due to
non-recognition of deferred tax asset on impairment.
- Diluted earnings per share is at Rs. 1.19.
Other Highlights:
- EBITDA at Rs. 11.9 billion and the EBITDA margin is
24.0%
- Capital expenditure is at Rs. 2.9 billion.
- Free cash-flow: Net out-flow during the quarter stood at
Rs. 580 million.
- Net cash surplus for the company is at Rs. 839 million
as on December 31, 2020. Consequently, net debt to equity ratio is
(0.005).
Earnings Call Details (05:30 pm IST, 07:00 am EST, Jan 29,
2021)
The management of the Company will host an earnings call to
discuss the Company’s financial performance and answer any
questions from the participants.
Conference Joining Information
Option 1: Express Join with
DiamondPass™
Pre-register with the below link and join without waiting for
the operator.
https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=9941549&linkSecurityString=1ea6b66bb2
Option 2: Join through below Dial-In
Numbers
Universal Access Number:
+91 22 6280 1219
+91 22 7115 8120
Local Access Number:
Available all over India
+91 70456 71221
International Toll Free Number:
USA: 1 866 746 2133
UK: 0 808 101 1573
Singapore: 800 101 2045
Hong Kong: 800 964 448
No password/pin number is necessary to dial in to any of the
above numbers. The operator will provide instructions on asking
questions before and during the call.
Play Back: The play back will be available after the
earnings call, till February 5th, 2021. For play back dial in phone
No: +91 22 7194 5757 | +91 22 6663 5757, and Playback Code is
37918.
Transcript: Transcript of the Earnings call will be
available on the Company’s website: www.drreddys.com
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy’s operates in
markets across the globe. Our major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on
the management’s current views and assumptions and involve known or
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. In addition to statements which are
forward-looking by reason of context, the words "may", "will",
"should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar
expressions identify forward-looking statements. Actual results,
performance or events may differ materially from those in such
statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates , interest rates , persistency
levels and frequency / severity of insured loss events (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization ,
including related integration issues, (vi) the susceptibility of
our industry and the markets addressed by our, and our customers’,
products and services to economic downturns as a result of natural
disasters, epidemics, pandemics or other widespread illness,
including coronavirus (or COVID-19), and (vii) other risks and
uncertainties identified in our public filings with the Securities
and Exchange Commission, including those listed under the "Risk
Factors" and "Forward-Looking Statements" sections of our Annual
Report on Form 20-F for the year ended March 31, 2020. The company
assumes no obligation to update any information contained
herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210129005174/en/
INVESTOR RELATIONS AMIT AGARWAL amita@drreddys.com (Ph:
+91-40-4900 2135)
MEDIA RELATIONS APARNA TEKURI aparnatekuri@drreddys.com
(Ph: +91-40-4900 2446)
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Sep 2023 to Sep 2024